揭示细胞变态的秘密：EndMT机制在covid -19诱导的肺纤维化中的关键作用。

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-09-24 DOI:10.1007/s10787-025-01927-3

Xin Zhang, Xia Tong, Ruijie Hou, Pengbo Wang, Yan Mo, Lanlan Zhang

{"title":"揭示细胞变态的秘密：EndMT机制在covid -19诱导的肺纤维化中的关键作用。","authors":"Xin Zhang, Xia Tong, Ruijie Hou, Pengbo Wang, Yan Mo, Lanlan Zhang","doi":"10.1007/s10787-025-01927-3","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic has resulted in several long-term complications, with COVID-19-induced pulmonary fibrosis being a significant concern. Despite increasing recognition, the mechanisms underlying its development, effective treatment strategies, and long-term outcomes remain poorly understood. Emerging research highlights the direct impact of SARS-CoV-2 on vascular endothelial cells, identifying endothelial-mesenchymal transition (EndMT) as a key factor in the progression of COVID-19-induced pulmonary fibrosis. However, there is a notable lack of comprehensive reviews addressing the link between EndMT and COVID-19-induced pulmonary fibrosis. This review seeks to fill that gap by providing an in-depth analysis of the relationship between EndMT and fibrosis, examining relevant risk factors and molecular pathways. Our findings offer critical insights that could inform the development of targeted anti-fibrotic therapies aimed at mitigating COVID-19-related pulmonary fibrosis. Ultimately, this review aims to advance understanding of the role of EndMT in pulmonary fibrosis and to guide future research and treatment approaches.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unveiling the secret of cellular metamorphosis: the crucial role of EndMT mechanisms in COVID-19-induced pulmonary fibrosis.\",\"authors\":\"Xin Zhang, Xia Tong, Ruijie Hou, Pengbo Wang, Yan Mo, Lanlan Zhang\",\"doi\":\"10.1007/s10787-025-01927-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 pandemic has resulted in several long-term complications, with COVID-19-induced pulmonary fibrosis being a significant concern. Despite increasing recognition, the mechanisms underlying its development, effective treatment strategies, and long-term outcomes remain poorly understood. Emerging research highlights the direct impact of SARS-CoV-2 on vascular endothelial cells, identifying endothelial-mesenchymal transition (EndMT) as a key factor in the progression of COVID-19-induced pulmonary fibrosis. However, there is a notable lack of comprehensive reviews addressing the link between EndMT and COVID-19-induced pulmonary fibrosis. This review seeks to fill that gap by providing an in-depth analysis of the relationship between EndMT and fibrosis, examining relevant risk factors and molecular pathways. Our findings offer critical insights that could inform the development of targeted anti-fibrotic therapies aimed at mitigating COVID-19-related pulmonary fibrosis. Ultimately, this review aims to advance understanding of the role of EndMT in pulmonary fibrosis and to guide future research and treatment approaches.\",\"PeriodicalId\":13551,\"journal\":{\"name\":\"Inflammopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10787-025-01927-3\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01927-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

COVID-19大流行导致了几种长期并发症，COVID-19诱导的肺纤维化是一个重大问题。尽管越来越多的人认识到，其发展的机制，有效的治疗策略和长期结果仍然知之甚少。新研究强调了SARS-CoV-2对血管内皮细胞的直接影响，发现内皮-间充质转化（EndMT）是covid -19诱导的肺纤维化进展的关键因素。然而，值得注意的是，缺乏针对EndMT与covid -19诱导的肺纤维化之间联系的全面综述。本综述旨在通过深入分析EndMT与纤维化之间的关系，检查相关危险因素和分子途径来填补这一空白。我们的研究结果提供了重要的见解，可以为开发靶向抗纤维化疗法提供信息，旨在减轻covid -19相关的肺纤维化。最终，本综述旨在促进对EndMT在肺纤维化中的作用的理解，并指导未来的研究和治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unveiling the secret of cellular metamorphosis: the crucial role of EndMT mechanisms in COVID-19-induced pulmonary fibrosis.

The COVID-19 pandemic has resulted in several long-term complications, with COVID-19-induced pulmonary fibrosis being a significant concern. Despite increasing recognition, the mechanisms underlying its development, effective treatment strategies, and long-term outcomes remain poorly understood. Emerging research highlights the direct impact of SARS-CoV-2 on vascular endothelial cells, identifying endothelial-mesenchymal transition (EndMT) as a key factor in the progression of COVID-19-induced pulmonary fibrosis. However, there is a notable lack of comprehensive reviews addressing the link between EndMT and COVID-19-induced pulmonary fibrosis. This review seeks to fill that gap by providing an in-depth analysis of the relationship between EndMT and fibrosis, examining relevant risk factors and molecular pathways. Our findings offer critical insights that could inform the development of targeted anti-fibrotic therapies aimed at mitigating COVID-19-related pulmonary fibrosis. Ultimately, this review aims to advance understanding of the role of EndMT in pulmonary fibrosis and to guide future research and treatment approaches.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]